NO20020208L - Flytende sammensetninger for oral administrasjon - Google Patents

Flytende sammensetninger for oral administrasjon

Info

Publication number
NO20020208L
NO20020208L NO20020208A NO20020208A NO20020208L NO 20020208 L NO20020208 L NO 20020208L NO 20020208 A NO20020208 A NO 20020208A NO 20020208 A NO20020208 A NO 20020208A NO 20020208 L NO20020208 L NO 20020208L
Authority
NO
Norway
Prior art keywords
oral administration
liquid compositions
compositions
liquid
oral
Prior art date
Application number
NO20020208A
Other languages
English (en)
Other versions
NO20020208D0 (no
Inventor
Edward S Wilson
Laura A Trespidi
Christy M Clark
Ashok J Desai
Glenn A Meyer
Frederick D Sancilio
Original Assignee
Aai Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US09/354,982 priority Critical patent/US6365180B1/en
Priority to PCT/US2000/019372 priority patent/WO2001013897A1/en
Application filed by Aai Pharma Inc filed Critical Aai Pharma Inc
Publication of NO20020208D0 publication Critical patent/NO20020208D0/no
Publication of NO20020208L publication Critical patent/NO20020208L/no
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23395748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20020208(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
NO20020208A 1998-01-20 2002-01-15 Flytende sammensetninger for oral administrasjon NO20020208L (no)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/354,982 US6365180B1 (en) 1998-01-20 1999-07-16 Oral liquid compositions
PCT/US2000/019372 WO2001013897A1 (en) 1999-07-16 2000-07-14 Oral liquid compositions

Publications (2)

Publication Number Publication Date
NO20020208D0 NO20020208D0 (no) 2002-01-15
NO20020208L true NO20020208L (no) 2002-03-18

Family

ID=23395748

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020208A NO20020208L (no) 1998-01-20 2002-01-15 Flytende sammensetninger for oral administrasjon

Country Status (18)

Country Link
US (1) US6365180B1 (no)
EP (1) EP1196147A4 (no)
JP (1) JP2003507415A (no)
KR (1) KR20020050223A (no)
CN (1) CN1407887A (no)
AU (1) AU770772B2 (no)
BR (1) BR0012488A (no)
CA (1) CA2376180A1 (no)
CZ (1) CZ2002129A3 (no)
HR (1) HRP20020045A2 (no)
MX (1) MXPA02000583A (no)
NO (1) NO20020208L (no)
RU (1) RU2252019C2 (no)
SI (1) SI20849A (no)
SK (1) SK572002A3 (no)
UA (1) UA80085C2 (no)
WO (1) WO2001013897A1 (no)
ZA (1) ZA200200741B (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602467B1 (en) * 1998-07-24 2003-08-05 Therox, Inc. Apparatus and method for blood oxygenation
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
JP4865958B2 (ja) * 2001-05-23 2012-02-01 エスエス製薬株式会社 鎮痛抗炎症局所作用型の貼付剤
US7855082B1 (en) 2001-10-31 2010-12-21 Astrazeneca Ab Raman spectroscopic method for determining the ratio of 5-methoxy and 6-methoxy isomers of omeprazole
US20040006109A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
WO2004028456A2 (en) * 2002-09-26 2004-04-08 Myriad Genetics, Inc Method and composition for treating neurodegenerative disorders
ITMI20022777A1 (it) * 2002-12-27 2004-06-28 Altergon Sa Formulazioni farmaceutiche per ormoni tiroidei e procedimenti per il loro ottenimento.
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
CA2517005A1 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
CA2532207A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
JP2006528181A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 酸分泌を阻害するために有用な薬学的製剤ならびにそれらを作製および使用する方法
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US20050249806A1 (en) * 2004-02-10 2005-11-10 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
US20050203115A1 (en) * 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
WO2005108683A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ITMI20041245A1 (it) * 2004-06-22 2004-09-22 Ibsa Inst Biochimique Sa Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US20060088590A1 (en) * 2004-10-22 2006-04-27 Banner Pharmacaps, Inc. Non-blooming gelatin and non-gelatin formulations
WO2006052921A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Cyclodextrin solubilizers for liquid and semi-solid formulations
WO2006052922A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
US20070053868A1 (en) 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
WO2006134877A1 (ja) * 2005-06-13 2006-12-21 Takeda Pharmaceutical Company Limited 注射剤
WO2006138534A2 (en) * 2005-06-15 2006-12-28 Morton Grove Pharmaceuticals, Inc. Stable warfarin sodium liquid formulation and method of making same
JO3352B1 (ar) * 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
CA2613631A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
BRPI0613611A2 (pt) * 2005-07-22 2011-01-18 Myriad Genetics Inc formulações de alta concentração de fármaco e formas de dosagens
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
CN101360485B (zh) * 2005-10-26 2013-04-17 班纳制药公司 作为胶囊填充物的基于亲水性载体的双重控释基质系统
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
WO2007112272A2 (en) * 2006-03-28 2007-10-04 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
BRPI0709410A2 (pt) * 2006-03-28 2011-07-12 Javelin Pharmaceuticals Inc composição farmacêutica e método para tratar um mamìfero necessitando de um agente analgésico, anti-inflamatório ou um antipirético
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
US20100316712A1 (en) * 2006-12-22 2010-12-16 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008141888A1 (en) * 2007-05-24 2008-11-27 Novartis Ag Oral dosage form providing fast absorption of drug
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US7662858B2 (en) 2008-05-23 2010-02-16 Aaipharma, Inc. Method of treating post-surgical acute pain
KR101096429B1 (ko) * 2008-07-18 2011-12-20 한국유나이티드제약 주식회사 안정성이 향상된 아세클로페낙의 경구용 연질캅셀제
JP2013520521A (ja) * 2009-11-09 2013-06-06 ゼノポート,インコーポレーテッド レボドパプロドラッグの医薬組成物及び経口剤形並びに使用方法
KR101346750B1 (ko) * 2010-06-07 2013-12-31 한국콜마주식회사 나프록센 액상 조성물을 함유하는 밀봉된 경질캡슐제
GB201021267D0 (en) * 2010-12-15 2011-01-26 Reckitt Benckiser Healthcare Int Ltd Novel pharmaceutical formulation
NZ728268A (en) * 2011-07-27 2019-02-22 B Athanassiadis Dental Pty Ltd Alkaline compositions and their dental and medical use
WO2013058996A1 (en) 2011-10-19 2013-04-25 R.P. Scherer Technologies, Llc Two phase pharmaceutical delivery system
WO2014060855A1 (en) 2012-10-16 2014-04-24 Wockhardt Limited Pharmaceutical compositions of diclofenac or salts thereof
US20150250751A1 (en) 2012-10-16 2015-09-10 Wockhardt Limited Pharmaceutical compositions of diclofenac or salts thereof
US20150238451A1 (en) 2012-10-19 2015-08-27 Wockhardt Limited Pharmaceutical compositions of diclofenac or salts thereof
CN106456595A (zh) 2014-02-10 2017-02-22 帕塔拉制药有限责任公司 用于系统性病症的肥大细胞稳定剂治疗
RS58972B1 (sr) 2014-10-21 2019-08-30 Abbvie Inc Karbidopa i l-dopa prolekovi i njihova primena za lečenje parkinsonove bolesti
CN107427463A (zh) 2015-01-20 2017-12-01 艾伯维公司 左旋多巴和卡比多巴肠凝胶以及使用方法
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
JP2019528320A (ja) 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh 特発性肺線維症による慢性咳の治療のためのクロモリン組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4028772A (en) 1971-04-02 1973-09-27 Merck & Co., Inc Chemical processes
HU185926B (en) 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US4880835A (en) 1988-11-03 1989-11-14 Formulations Development Labs, Inc. Oral liquid pharmaceutical compositions of sulindac
JPH0717498B2 (ja) * 1989-05-31 1995-03-01 興和株式会社 鎮咳去痰ソフトカプセル剤
CA2017916C (en) 1989-06-07 1999-02-02 Minoru Aoki Etoposide preparations
US5024997A (en) * 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
US5141961A (en) * 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives
US5183829A (en) * 1991-09-27 1993-02-02 Applied Analytical Industries, Inc. Oral liquid compositions of non-steroidal anti-inflammatory drugs
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
US5505961A (en) 1993-08-05 1996-04-09 R. P. Scherer Corporation Gelatin capsules containing a highly concentrated acetaminophen solution
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
SK96196A3 (en) * 1994-01-24 1997-03-05 Procter & Gamble Process for solubilizing difficultly soluble pharmaceutical actives
ES2088742B1 (es) * 1994-06-29 1997-03-16 Salvat Lab Sa Composicion antibiotica de aplicacion otica.
CA2141126A1 (en) * 1995-01-26 1996-07-27 Natalie J. Lazarowych Combinational drug for treating migraine and other illnesses
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US5516789A (en) * 1995-04-12 1996-05-14 Abbott Laboratories Lipoxygenase and cyclooxygenase inhibiting compounds
US6013280A (en) 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
IT1295369B1 (it) * 1997-10-21 1999-05-12 Fatro Spa Composizione a base di tiamfenicolo e diclofenac
CA2318128C (en) * 1998-01-20 2008-10-14 Applied Analytical Industries, Inc. Oral liquid compositions

Also Published As

Publication number Publication date
UA80085C2 (en) 2007-08-27
WO2001013897A1 (en) 2001-03-01
NO20020208D0 (no) 2002-01-15
CA2376180A1 (en) 2001-03-01
US6365180B1 (en) 2002-04-02
HRP20020045A2 (en) 2006-06-30
JP2003507415A (ja) 2003-02-25
RU2252019C2 (ru) 2005-05-20
AU6216800A (en) 2001-03-19
SK572002A3 (en) 2002-08-06
ZA200200741B (en) 2003-06-25
KR20020050223A (ko) 2002-06-26
EP1196147A4 (en) 2005-04-20
AU770772B2 (en) 2004-03-04
EP1196147A1 (en) 2002-04-17
BR0012488A (pt) 2002-04-02
SI20849A (sl) 2002-10-31
MXPA02000583A (es) 2003-10-14
CZ2002129A3 (cs) 2002-08-14
CN1407887A (zh) 2003-04-02

Similar Documents

Publication Publication Date Title
DK1104760T3 (da) Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
DZ1876A1 (fr) Médicaments pour administration orale.
DE60016271D1 (de) Medikamentenzuführvorrichtung
NO20030418L (no) Nytt farmasöytisk preparat
NO20033715L (no) Nye sammensetninger
RU2002103509A (ru) Фармацевтические соединения
NO20020976L (no) Retarderte, orale, farmasöytiske administreringsformer
AT265850T (de) Ibuprofenhaltige arzneizubereitung
NO20015379L (no) Indolinderivater som progesteronantagonister
NO971898D0 (no) Farmasöytiske preparater
NO20023684L (no) Pediatrisk formulering
NO20021974L (no) Fargemerkede imidazokinolinforbindelser
DK1223903T3 (da) Væskefrakturhånddel
NO971951L (no) Farmasöytiske preparater
DK1223902T3 (da) Væskefrakturhånddel
DE69904057D1 (de) Orale flüssige mucoadhäsive zusammensetzungen
DK1117440T3 (da) Farmaceutiske sammensætninger indeholdende paclitaxel
NO20020275L (no) Imidazoimidazoler og -triazoler som anti-inflammatoriske midler
NO995925D0 (no) Farmasöytiske sammensetninger omfattende cyklodekstriner
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
DE69807756D1 (de) Fotopolymerisierbare dentalzusammensetzungen
IS6263A (is) Lyfjasamsetningar, sem innihalda trípeptíð
NO20022998L (no) Farmasöytiske preparater som tilveiebringer foröket konsentrasjon av medikament
IS6994A (is) Arípíprazóllausn til gjafar um munn
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application